Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gammaplex 10 vs 5% Bioequivalence in Primary Immunodeficiency
NCT01963143Phase 3Completed
- Sponsor
- Bio Products Laboratory
- Start
- Feb 2014
- Primary completion
- Jan 2016
- Modality
- Biologic
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of polyvalent human immunoglobulin in primary immunodeficiency disease (PID) (3 arms), sponsored by Bio Products Laboratory. Primary endpoint: Area Under the Curve Within a 28-day Dosing Interval. Started Feb 2014; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT01963143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01963143.